Kyverna Therapeutics (“Kyverna”), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the signing of a multi-year research funding agreement with Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology to investigate the impact of B- and plasma cell-targeting therapies.
